Key result
The atorvastatin-fenofibrate combination reduced LDL cholesterol by 46% and triglycerides by 50%, and increased HDL cholesterol by 22%, significantly more than either monotherapy (P<0.0001 for all).
Why the study?
Does the combination of atorvastatin and fenofibrate improve lipid profiles compared to either drug alone in patients with type 2 diabetes and combined hyperlipidemia?
Population
120 patients with type 2 diabetes and combined hyperlipidemia, free of coronary artery disease at entry.
Comparison
Combination of atorvastatin 20 mg/day plus… vs Atorvastatin 20 mg/day alone or micronized…
Design
RCT, Randomly assigned
Follow-up
24 weeks
Authors
Loading...
Combination may improve lipids vs monotherapy in T2DM with CHL; leaves open CAD outcome benefits.
RCT (n=120)
randomly assigned
Does the combination of atorvastatin and fenofibrate improve lipid profiles compared to either drug alone in patients with type 2 diabetes and combined hyperlipidemia?
p-value: p=<0.0001
Combination therapy with atorvastatin and fenofibrate is highly effective at improving lipid profiles and reducing estimated CAD risk in patients with type 2 diabetes and combined hyperlipidemia compared to monotherapy.
Athyros et al. (2002) conducted an RCT in Type 2 diabetes with combined hyperlipidemia (n=120). Atorvastatin-fenofibrate combination vs. Atorvastatin 20 mg/day or micronized fenofibrate 200 mg/day alone was evaluated on Changes in lipid profile (total cholesterol, LDL cholesterol, triglycerides, HDL cholesterol, and plasma fibrinogen) (p=<0.0001). The atorvastatin-fenofibrate combination reduced LDL cholesterol by 46% and triglycerides by 50%, and increased HDL cholesterol by 22%, significantly more than either monotherapy (P<0.0001 for all).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: